Omeros Corporation  

(Public, NASDAQ:OMER)   Watch this stock  
Find more results for OMER
13.73
-0.19 (-1.36%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.53 - 14.25
52 week 4.75 - 18.80
Open 14.05
Vol / Avg. 0.00/480,718.00
Mkt cap 465.62M
P/E     -
Div/yield     -
EPS -1.55
Shares 33.91M
Beta 0.99
Inst. own 39%
Aug 11, 2014
Omeros Corp at Wedbush Securities Life Sciences Conference - 8:00PM EDT - Add to calendar
Aug 4, 2014
Q2 2014 Omeros Corporation Earnings Release (Estimated) Add to calendar
Jun 2, 2014
Omeros' Omidria FDA Approval Conference Call
May 23, 2014
Omeros Corporation Annual Shareholder Meeting
May 12, 2014
Q1 2014 Omeros Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -16642.00% -2487.25%
Operating margin -15684.00% -2376.00%
EBITD margin - -3138.38%
Return on average assets -183.88% -184.63%
Return on average equity - -
Employees 75 -
CDP Score - -

Address

201 Elliott Avenue West
SEATTLE, WA 98119
United States - Map
+1-206-6765000 (Phone)
+1-206-6765005 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system. The Company develops pharmaceutical and therapeutic approaches to the management of surgical pain and inflammation, vasospasm, smooth muscle spasm, vascular restenosis and implantable surgical devices. Omeros develops products that are delivered directly to the site of tissue injury, preemptively inhibiting inflammation, pain and other problems associated with medical and surgical procedures.

Officers and directors

Gregory A. Demopulos M.D. Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Michael A. Jacobsen Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 55
Bio & Compensation  - Reuters
Marcia S. Kelbon J.D. Vice President - Patent, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
Thomas J. Cable Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Peter A. Demopulos M.D. Director
Age: 60
Bio & Compensation  - Reuters
Ray Aspiri Independent Director
Age: 77
Bio & Compensation  - Reuters
Arnold C. Hanish Independent Director
Age: 66
Bio & Compensation  - Reuters
Leroy E. Hood M.D., Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters